Valeant Pharma (VRX) Corrects adj.-EBITDA Guidance Lower to ~$6B on Call
Valeant Pharma (NYSE: VRX) corrected EBITDA guidance for the next four quarters to about $6 billion on its earning call. An earlier release forecast next four quarters (second quarter 2016 – first quarter 2017) guidance of about $6.2 - $6.6 billion.
Shares are lower by 36 percent.